Mind Medicine Inc’s recent filing unveils that its Chief Legal Officer Sullivan Mark unloaded Company’s shares for reported $78139.0 on Jun 25 ’25. In the deal valued at $6.80 per share,11,491 shares were sold. As a result of this transaction, Sullivan Mark now holds 305,130 shares worth roughly $2.2 million.
Then, Karlin Daniel sold 7,848 shares, generating $53,366 in total proceeds. Upon selling the shares at $6.80, the Chief Medical Officer now owns 438,329 shares.
Before that, Barrow Robert sold 26,491 shares. Mind Medicine Inc shares valued at $180,139 were divested by the Chief Executive Officer at a price of $6.80 per share. As a result of the transaction, Barrow Robert now holds 830,065 shares, worth roughly $5.98 million.
Evercore ISI initiated its Mind Medicine Inc [MNMD] rating to an Outperform in a research note published on January 28, 2025; the price target was $23. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. ROTH MKM started covering the stock on July 24, 2024. It rated MNMD as “a Buy”.
Price Performance Review of MNMD
On Monday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock jump 0.42% to $7.2. Over the last five days, the stock has gained 9.92%. Mind Medicine Inc shares have risen nearly 3.45% since the year began. Nevertheless, the stocks have risen 3.45% over the past one year. While a 52-week high of $10.44 was reached on 02/14/25, a 52-week low of $4.70 was recorded on 04/09/25.
Levels Of Support And Resistance For MNMD Stock
The 24-hour chart illustrates a support level at 6.97, which if violated will result in even more drops to 6.74. On the upside, there is a resistance level at 7.41. A further resistance level may holdings at 7.61.
How much short interest is there in Mind Medicine Inc?
A steep rise in short interest was recorded in Mind Medicine Inc stocks on 2025-06-13, dropping by -0.43 million shares to a total of 11.07 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 11.5 million shares. There was a decline of -3.9%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 29, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $27 price target.
